ScholarIQanswers from OpenAlex
Naval University of Engineering
InstitutionResearch output, impact & collaborations
Naval University of Engineering is a institution indexed in ScholarIQ from OpenAlex.
What is known about Naval University of Engineering?
ScholarIQrecord summary
Naval University of Engineering is a research organisation in Wuhan, CN. OpenAlex records 20,247 works and 299,093 citations for it. 6,686 researchers list it as their most recent affiliation.
How many works does Naval University of Engineering have?
ScholarIQindexed works
Naval University of Engineering has 20,247 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Naval University of Engineering have?
ScholarIQcitation count
Naval University of Engineering has 299,093 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Naval University of Engineering?
ScholarIQresearcher count
Naval University of Engineering has 6,686 researchers in the ScholarIQ index.
What is the average h-index at Naval University of Engineering?
ScholarIQavg h-index
Naval University of Engineering has an average h-index of 49.8 in OpenAlex.
What is the ROR of Naval University of Engineering?
ScholarIQror
The ROR for Naval University of Engineering is on the source record.
What is the OpenAlex record for Naval University of Engineering?
ScholarIQopenalex
The OpenAlex for Naval University of Engineering is on the source record.
What is the Wikidata of Naval University of Engineering?
ScholarIQwikidata
The Wikidata for Naval University of Engineering is on the source record.
Who are the most-cited researchers behind Naval University of Engineering?
ScholarIQtop researchers by citations
What are the most-cited papers on Naval University of Engineering?
ScholarIQmost cited works
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Bárbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp, Jerónimo Rafael Rodríguez‐Cid, Jonathan Wilson, Shunichi Sugawara, Terufumi Kato, Ki Hyeong Lee, Ying Cheng, Silvia Novello, Balázs Halmos, Xiaodong Li, Gregory M. Lubiniecki, Bilal Piperdi, Dariusz M. Kowalski
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony Mok, Yi‐Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, H.Z. Turna, Gilberto de Castro, Vichien Srimuninnimit, К. К. Лактионов, Igor Bondarenko, Kaoru Kubota, Gregory M. Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes, Grigory Adamchuk, Myung‐Ju Ahn, Aurelia Alexandru, Özden Altundağ, Anna Alyasova, Orest Andrusenko, Keisuke Aoe, António Araújo, Osvaldo Rudy Aren, Oscar Arrieta Rodriguez, Touch Ativitavas, Oscar Avendaño, Fernando Barata, Carlos H. Barrios, Carlos Beato, Per Bergström, Daniel Betticher, Л. В. Болотина, Igor Bondarenko, Michiel Botha, Sayeuri Buddu, Christian Caglevic, Andrés F. Cardona, Gilberto de Castro, Hugo R. Castro, Filiz Çay Şenler, Carlos Alexandre Sydow Cerny, Alvydas Česas, Gee-Chen Chan, Jianhua Chang, Gongyan Chen, Xi Chen, Susanna Cheng, Ying Cheng, Nelly Cherciu, Chao‐Hua Chiu, Byoung Chul Cho, Saulius Cicėnas, Daniel Ciurescu, Graham Cohen, Marcos André Costa, Pongwut Danchaivijitr, Flávia De Angelis, Sérgio Jobim Azevedo, Mircea Dediu, Tsvetan Deliverski, Pedro Rafael Martins De Marchi, Flor de The Bustamante Valles, Zhenyu Ding, Boyan Doganov, Lydia Dreosti, Ricardo Duarte, Regina Edusma-Dy, S. A. Emelyanov, Mustafa Erman, Yun Fan, Luis Fein, Jifeng Feng, David Fenton, Gustavo dos Santos Fernandes, Carlos Gil Ferreira, Fábio Franke, H. Freitas, Yasuhito Fujisaka, Héctor Galindo, Christina Galvez, Doina Ganea, Nuno Gil, Gustavo Girotto, Erdem Göker, Tuncay Göksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, Håkan Griph, Mahmut Gümüş, Jacqueline A. Hall, Gregory Hart, Libor Havel, Jianxing He, Yong He, Carlos Hernández Hernández, Venceslau Hespanhol, Tomonori Hirashima, Chung Man James Ho, Atsushi Horiike
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony Mok
How much of the research on Naval University of Engineering is open access?
ScholarIQopen access share
67%OPEN ACCESS